U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3
Molecular Weight 138.121
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALICYLIC ACID

SMILES

c1ccc(c(c1)C(=O)O)O

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI
Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Salicylic acid is obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.

CNS Activity

Originator

Approval Year

1860
15
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
Inhibitor
7728
Inhibitor
7728
 1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8043
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
Approved
8043
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
Approved
8043
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Palliative
Approved
8043
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1.20346562E12
Primary
Approved
8043
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Approved
8043
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
Primary
Approved
8043
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1.35501119E12
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
EXPERIMENT
https://www.sciencedirect.com/science/article/abs/pii/S0022354915364558
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/27904577/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601
substrate
936
substrate
1118

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
634

CYP2C19
910

CYP2E1
606

CYP2A6
485

CYP2B6
616

UGT1A1
393

UGT1A3
397

UGT1A4
330

UGT1A6
289

UGT1A7
221

UGT1A8
266

UGT1A9
357

UGT1A10
273

UGT2B4
233

UGT2B7
362

UGT2B15
191

UGT2B17
203
CYP2E1
117
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2E1
871
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
485
 likely
CYP2B6
616
 likely
CYP2E1
606
 major
UGT1A4
330
 no
UGT2B15
191
 no
UGT2B17
203
 no
CYP2C19
910
 yes
CYP2C8
634
 yes
CYP2C9
936
 yes
CYP2D6
1118
 yes
CYP3A4
1601
 yes
UGT1A1
393
 yes
UGT1A10
273
 yes
UGT1A3
397
 yes
UGT1A6
289
 yes
UGT1A7
221
 yes
UGT1A8
266
 yes
UGT1A9
357
 yes
UGT2B4
233
 yes
UGT2B7
362
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:16914
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16914
ChemicalBook
CB1680010
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1680010
MolPort
MolPort-001-769-476
https://www.molport.com/shop/molecule-link/MolPort-001-769-476
ZINC
ZINC000000001554
http://zinc15.docking.org/substances/ZINC000000001554
eMolecules
478035
https://www.emolecules.com/cgi-bin/more?vid=478035
PubMed

PubMed

TitleDatePubMed
[Identification and quantification of exogenous metabolites in biological liquids with new development in NMR spectroscopy in one and two dimensions].
1999
Salicylate attenuates gentamicin-induced ototoxicity.
1999 Jul
Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE).
1999 May
Effects of salicylates on evoked otoacoustic emissions and remote masking in humans.
1999 May-Jun
False-high blood salicylate levels in neonates with hyperbilirubinemia.
2000 Dec
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.
2001 Apr
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
2001 Apr
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
2001 Apr 13
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
2001 Apr 30
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.
2001 Jan
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane.
2001 Jan
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid.
2001 Jan
Free and conjugated benzoic acid in tobacco plants and cell cultures. Induced accumulation upon elicitation of defense responses and role as salicylic acid precursors.
2001 Jan
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
2001 Jan 15
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Pathogen-induced expression of plant ATP: citrate lyase.
2001 Jan 19
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia.
2001 Jan-Feb
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.
2001 Mar
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
Identification of free radicals produced during phacoemulsification.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Patents

Patents

JPH05214268A
12
JPS62238231A
12
JPS63211254A
12
US1814853
12
US20130266535
12
US2113374
12
US3359307
12
US4137258
12

Sample Use Guides

In Vivo Use Guide
adults 18 years and older: apply one patch to affected area and leave in place for up to 8-12 hours; if pain lasts lasts after using the first patch, a second patch may be applied for up to another 8 to 12 hours; use only one patch at a time; do not use more than 2 patches per day; do not use for more 3 days in a row
Route of Administration: Topical
In Vitro Use Guide
In vitro tests with fresh dermatomed (0.3 to 0.4 mm thick) female breast skin and one leg skin specimen were conducted in Bronaugh flow-through Teflon diffusion cells with three chemicals used to simulate chemical warfare agents: 14C-radiolabeled methyl salicylate (MES), ethyl parathion (PT), and malathion (MT), at three dose levels (2, 20, and 200 mM). Tests were conducted at a skin temperature of 29 degrees C using a brief 30-min exposure to the chemical and a 6.5-h receivor collection period. Rapid absorption of all three chemicals was observed, with MES absorbed about 10-fold faster than PT and MT. For MES, PT, and MT, respectively, there was 32%, 7%, and 12% absorption into the receivor solution at the low dose (2 mM), 17%, 2%, and 3% at the medium dose (20 mM), and 11%, 1%, and 1% at the high dose (200 mM) levels. Including the skin depot for MES, PT, and MT, respectively, there was 40%, 41%, and 21% (low dose), 26%, 16%, and 8% (medium dose), and 13%, 19%, and 10% (high does) absorption.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:17 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:17 UTC 2021
Record UNII
O414PZ4LPZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SALICYLIC ACID
EP   GREEN BOOK   HSDB   INCI   JAN   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
MESALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [USP-RS]
Common Name English
LAMIVUDINE RELATED COMPOUND SALICYLIC ACID [USP]
Common Name English
2-HYDROXYBENZENECARBOXYLIC ACID
Systematic Name English
COMPOUND W
Brand Name English
SALICYLIC ACID [WHO-DD]
Common Name English
SALICYLIC ACID [JAN]
Common Name English
SALICYLIC ACID [VANDF]
Common Name English
SALICYLIC ACID [INCI]
Common Name English
DR. SCHOLL'S CALLUS REMOVERS
Brand Name English
SALICYLICUM ACIDUM
HPUS  
Common Name English
FEMA NO. 3985
Code English
SALICYLIC ACID [MART.]
Common Name English
SALICYLICUM ACIDUM [HPUS]
Common Name English
SALICYLIC ACID [GREEN BOOK]
Common Name English
SALICYLIC ACID [MI]
Common Name English
SALICYLIC ACID [HSDB]
Common Name English
SALICYLATE
Systematic Name English
NSC-180
Code English
2-HYDROXYBENZOIC ACID [FHFI]
Common Name English
LAMIVUDINE IMPURITY C [EP]
Common Name English
2-HYDROXYBENZOIC ACID
FHFI  
Systematic Name English
ACIDUM SALICYLICUM [WHO-IP LATIN]
Common Name English
SALICYLIC ACID RS [USP]
Common Name English
SULFASALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [EP MONOGRAPH]
Common Name English
LAMIVUDINE IMPURITY, SALICYLIC ACID- [USP]
Common Name English
SALICYLIC ACID [WHO-IP]
Common Name English
SALICYLIC ACID [USP]
Common Name English
K-557
Code English
SALICYLIC ACID [EP]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 358.710
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 333.310
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C52588
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.510
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QD01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 862.3830
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
EPA PESTICIDE CODE 76602
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.720
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QS01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC S01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.110
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
FDA ORPHAN DRUG 359211
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QM02AC99
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
JECFA EVALUATION 2-HYDROXYBENZOIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC D01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
Code System Code Type Description
RXCUI
9525
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
HSDB
672
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
FDA UNII
O414PZ4LPZ
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
PUBCHEM
338
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
RXCUI
9522
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
ALTERNATIVE
LACTMED
Salicylic Acid
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EVMPD
SUB15180MIG
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WIKIPEDIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
CAS
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
USP_CATALOG
1609002
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
200-712-3
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MESH
D020156
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
IUPHAR
4306
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG CENTRAL
2416
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MERCK INDEX
M9739
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61934
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.
ChEMBL
CHEMBL424
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG BANK
DB00936
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EPA CompTox
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
Related Record Type Details
OAT-1
TRANSPORTER -> INHIBITOR
Structure of MERCURIC SALICYLATE
SALT/SOLVATE -> PARENT
Structure of SALICYLIC ACID MONOETHANOLAMINE
SALT/SOLVATE -> PARENT
Structure of MAGNESIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of AMMONIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of THEOBROMINE CALCIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of COLCHICINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of QUININE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of ZINC SALICYLATE
SALT/SOLVATE -> PARENT
Structure of MAGNESIUM SALICYLATE ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of PHYSOSTIGMINE SALICYLATE
SALT/SOLVATE -> PARENT
STEVIA REBAUDIUNA LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
Structure of DEXTROMETHORPHAN SALICYLATE
SALT/SOLVATE -> PARENT
Structure of TROLAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CINCHONIDINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of DEQUALINIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of BENZYDAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CHOLINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CHOLINE MAGNESIUM TRISALICYLATE
SALT/SOLVATE -> PARENT
Structure of IMIDAZOLE SALICYLATE
SALT/SOLVATE -> PARENT
MENYANTHES TRIFOLIATA LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
IRIS VERSICOLOR ROOT
PARENT -> CONSTITUENT ALWAYS PRESENT
Structure of SALCOLEX
SALT/SOLVATE -> PARENT
Structure of BISMUTH TRISALICYLATE
SALT/SOLVATE -> PARENT
Structure of CADMIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of PHENYLMERCURY SALICYLATE
SALT/SOLVATE -> PARENT
Structure of ZINC BORODISALICYLATE
SALT/SOLVATE -> PARENT
Structure of POTASSIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of BISMUTH SUBSALICYLATE
SALT/SOLVATE -> PARENT
Structure of DIETHYLAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of SALCOLEX ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of LITHIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CAFFEINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of DODECYLAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of ANTIPYRINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of SALICYLATE MEGLUMINE
SALT/SOLVATE -> PARENT
Structure of HYDROXYALUMINUM DISALICYLATE
SALT/SOLVATE -> PARENT
Structure of DIMETHOCAINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of THEOBROMINE SODIUM SALICYLATE ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of NICOTINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of TRIETHYLAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of ETHYLAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of THEOBROMINE SODIUM SALICYLATE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of STRONTIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of THEOPHYLLINE CALCIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of DIPHENHYDRAMINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of BETAINE SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CEROUS SALICYLATE
SALT/SOLVATE -> PARENT
GALIUM APARINE WHOLE
PARENT -> CONSTITUENT ALWAYS PRESENT
Structure of SODIUM SALICYLATE
SALT/SOLVATE -> PARENT
Structure of CALCIUM SALICYLATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ASPIRIN
PARENT -> METABOLITE ACTIVE
MINOR
URINE
Related Record Type Details
Structure of ASPIRIN
PARENT -> IMPURITY
IDENTIFIED AS IMPURITY C Limits: impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
Structure of SULFATE ION
IMPURITY -> PARENT
EP
Structure of SALICYLAMIDE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLORIDE ION
IMPURITY -> PARENT
EP
Structure of PHENOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of SULFATE ION
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
Structure of 4-HYDROXYISOPHTHALIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of SULFASALAZINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CHLORIDE ION
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
Structure of CHLORIDE ION
IMPURITY -> PARENT
USP
Structure of LAMIVUDINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of SULFATE ION
IMPURITY -> PARENT
USP
Structure of 4-HYDROXYBENZOIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of MESALAMINE
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of SALICYLIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966